Korro Bio, Inc.
Business
Korro Bio is a biopharmaceutical company developing a new class of genetic medicines based on RNA editing, specifically ADAR-mediated adenosine-to-inosine single-nucleotide edits on RNA. The company uses proprietary oligonucleotide-based therapeutics delivered via established modalities such as GalNAc conjugation for subcutaneous administration. Its pipeline includes wholly-owned programs targeting hyperammonemia (KRRO-121), alpha-1 antitrypsin deficiency, longevity and liver health, and amyotrophic lateral sclerosis, plus up to two partnered programs with Novo Nordisk in cardiometabolic disease. All programs are in research or preclinical development.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 6 | 2 | 0 | — | — | |
| Research and development | 66 | 64 | 57 | 42 | 61 | |
| General and administrative | 28 | 31 | 27 | 17 | 37 | |
| Long-lived asset impairment charge | 31 | 0 | — | — | — | |
| Restructuring charge | 4 | 0 | — | — | — | |
| Total operating expenses | 128 | 94 | 85 | 59 | 98 | |
| Loss from operations | −122 | −92 | −85 | −59 | −84 | |
| Other income, net | 5 | 8 | 3 | 976,000 | — | |
| Total other income, net | 5 | 8 | 3 | 976,000 | −266,000 | |
| Loss before provision for income taxes | −117 | −83 | −81 | −58 | −85 | |
| Provision for income taxes | −637,000 | −141,000 | −27,000 | 10,000 | −15,000 | |
| Net loss | −117 | −84 | −81 | −58 | −85 | |
| Unrealized (loss) gain on available-for-sale marketable securities | −26,000 | 184,000 | 0 | 2,000 | — | |
| Foreign currency translation adjustments, net | −30,000 | 84,000 | 0 | — | — | |
| Comprehensive loss | −117 | −83 | −81 | −58 | — | |
| Net loss per share, basic | −12.48 | −9.37 | −53.08 | −227.42 | — | |
| Net loss per share, diluted | −12.48 | −9.37 | −53.08 | −227.42 | — | |
| Weighted-average shares used in computing net loss per share, basic | 9 | 9 | 2 | 255,175 | — | |
| Weighted-average shares used in computing net loss per share, diluted | 9 | 9 | 2 | 255,175 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2023 2023-10-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 22 | 56 | 166 | 37 | 36 | |
| Short-term marketable securities | 53 | 70 | 0 | — | — | |
| Accounts receivable | 969,000 | 2 | 0 | — | — | |
| Prepaid expenses and other current assets | 6 | 4 | 3 | — | 1 | |
| Total current assets | 82 | 132 | 173 | — | 57 | |
| Property and equipment, net | 8 | 28 | 16 | — | 10 | |
| Operating lease right-of-use assets | 8 | 24 | 27 | — | 2 | |
| Restricted cash, net of current portion | 2 | 3 | 3 | — | 5 | |
| Long-term marketable securities | 10 | 37 | 0 | — | — | |
| Other non-current assets | 2 | 3 | 3 | — | 228,000 | |
| Total assets | 114 | 226 | 222 | — | 74 | |
| Accounts payable | 2 | 4 | 7 | — | 3 | |
| Accrued expenses and other current liabilities | 8 | 6 | 10 | — | 3 | |
| Operating lease liabilities, current portion | 3 | 1 | 2 | — | 3 | |
| Deferred revenue, current portion | 0 | 4 | 0 | — | — | |
| Total current liabilities | 12 | 15 | 19 | — | 9 | |
| Operating lease liabilities, net of current portion | 41 | 43 | 31 | — | 209,000 | |
| Deferred revenue, net of current portion | 8 | 6 | 0 | — | — | |
| Other non-current liabilities | 1 | 1 | 1 | — | 0 | |
| Total liabilities | 62 | 66 | 52 | — | 9 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | — | 0 | |
| Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 9,417,295 shares and 9,377,259 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 9,000 | 9,000 | 8,000 | — | 0 | |
| Additional paid-in capital | 435 | 427 | 353 | — | 3 | |
| Accumulated other comprehensive income | 212,000 | 268,000 | 0 | — | −5,000 | |
| Accumulated deficit | −384 | −267 | −183 | — | −102 | |
| Total stockholders' equity | 51 | 160 | 170 | — | −99 | |
| Total liabilities and stockholders' equity | 114 | 226 | 222 | — | 74 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −117 | −84 | −81 | −58 | −85 | |
| Non-cash lease expense | 730,000 | 3 | 4 | 1 | 1 | |
| Stock-based compensation expense | 8 | 4 | 2 | 1 | — | |
| Depreciation expense | 4 | 4 | 4 | 3 | 3 | |
| Net amortization of premiums and discounts on marketable securities | −489,000 | −2 | −80,000 | −145,000 | — | |
| Loss on disposal of property and equipment | 63,000 | 357,000 | 65,000 | 0 | 16,000 | |
| Accounts receivable | 727,000 | −2 | 0 | — | — | |
| Prepaid expenses and other current assets | −2 | −726,000 | 559,000 | −28,000 | −173,000 | |
| Accounts payable | −2 | −1 | 3 | 2 | −2 | |
| Accrued expenses and other current liabilities | 1 | −4 | 1 | −39,000 | −398,000 | |
| Deferred revenue | −2 | 9 | 0 | — | — | |
| Operating lease liabilities | −1 | 12 | 1 | −2 | −396,000 | |
| Other non-current assets | 270,000 | 340,000 | −2 | −123,000 | — | |
| Net cash used in operating activities | −79 | −60 | −67 | −54 | −76 | |
| Purchases of marketable securities | −26 | −146 | 0 | −54 | −92 | |
| Proceeds from maturities of marketable securities | 71 | 41 | 19 | 53 | — | |
| Purchases of property and equipment | −518,000 | −18 | −8 | −5 | −3 | |
| Net cash provided by (used in) investing activities | 44 | −123 | 11 | 11 | −66 | |
| Proceeds from PIPE financing, net of issuance costs | 0 | 67 | 0 | — | — | |
| Proceeds from exercises of stock options | 685,000 | 2 | 702,000 | 62,000 | — | |
| Net cash provided by financing activities | 685,000 | 69 | 188 | 18,000 | 1 | |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 64,000 | −4,000 | 0 | — | — | |
| Net decrease in cash, cash equivalents and restricted cash | −34 | −114 | 132 | −43 | −141 | |
| Property and equipment capitalized under tenant improvement allowance | 0 | 11 | 2 | 0 | — | |
| Purchases of property and equipment in accounts payable and accrued expenses | 0 | 48,000 | 2 | 402,000 | — | |
| Cash paid for income taxes | 1,000 | 141,000 | 27,000 | 11,000 | — | |
| Cash paid for operating lease liabilities | 6 | 3 | 3 | 2 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Korro Bio, Inc.'s CIK number?
Korro Bio, Inc.'s SEC CIK number is 0001703647 (1703647). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Korro Bio, Inc.'s SEC filings?
All of Korro Bio, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Korro Bio, Inc. last report earnings?
Korro Bio, Inc. (KRRO) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-210291). This is Korro Bio, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Korro Bio, Inc.'s most recent earnings 8-K?
Korro Bio, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001193125-26-210291. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Korro Bio, Inc.'s latest earnings 8-K →
Look up any company's CIK number →